AbbVie In Hot Seat Over HCV Drugs' Serious Liver Injury Risk

After adverse event reports in patients with underlying advanced liver damage, FDA requires AbbVie to add risk language to Viekira Pak and Technivie labels. AbbVie may not see much long-term damage, but Merck likely will gain more traction when it enters the hepatitis C market.